U.S. markets open in 5 hours 21 minutes
  • S&P Futures

    4,373.25
    -48.50 (-1.10%)
     
  • Dow Futures

    33,997.00
    -465.00 (-1.35%)
     
  • Nasdaq Futures

    15,196.25
    -129.75 (-0.85%)
     
  • Russell 2000 Futures

    2,195.50
    -32.80 (-1.47%)
     
  • Crude Oil

    71.09
    -0.88 (-1.22%)
     
  • Gold

    1,754.40
    +3.00 (+0.17%)
     
  • Silver

    22.43
    +0.10 (+0.44%)
     
  • EUR/USD

    1.1719
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    24.70
    +6.01 (+32.16%)
     
  • GBP/USD

    1.3670
    -0.0067 (-0.49%)
     
  • USD/JPY

    109.7240
    -0.1710 (-0.16%)
     
  • BTC-USD

    44,875.74
    -3,314.54 (-6.88%)
     
  • CMC Crypto 200

    1,117.33
    -108.20 (-8.83%)
     
  • FTSE 100

    6,867.55
    -96.09 (-1.38%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Insider Buying: The Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman Just Bought 77% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Whilst it may not be a huge deal, we thought it was good to see that the Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman, David Epstein, recently bought US$51k worth of stock, for US$6.66 per share. While that isn't the hugest buy, it actually boosted their shareholding by 77%, which is good to see.

View our latest analysis for Evelo Biosciences

The Last 12 Months Of Insider Transactions At Evelo Biosciences

Notably, that recent purchase by David Epstein is the biggest insider purchase of Evelo Biosciences shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$9.41. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

David Epstein purchased 17.70k shares over the year. The average price per share was US$5.41. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Evelo Biosciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data suggests Evelo Biosciences insiders own 0.5% of the company, worth about US$2.2m. We consider this fairly low insider ownership.

What Might The Insider Transactions At Evelo Biosciences Tell Us?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. Overall the buying isn't worth writing home about. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Evelo Biosciences insiders are doubting the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To help with this, we've discovered 5 warning signs (2 are a bit unpleasant!) that you ought to be aware of before buying any shares in Evelo Biosciences.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.